Dyne Therapeutics (NASDAQ:DYN) Lowered to Sell Rating by Wall Street Zen

Dyne Therapeutics (NASDAQ:DYN) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Sunday.

Several other research firms have also recently commented on DYN. Evercore ISI reduced their target price on shares of Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Monday, December 15th. HC Wainwright raised their price objective on shares of Dyne Therapeutics from $46.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Tudor Pickering set a $23.00 price objective on Dyne Therapeutics in a report on Tuesday, December 9th. Chardan Capital reissued a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, December 9th. Finally, Stifel Nicolaus raised their price target on Dyne Therapeutics from $36.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $38.47.

Dyne Therapeutics Stock Down 1.5%

Dyne Therapeutics stock opened at $20.04 on Friday. The stock has a 50 day moving average of $20.17 and a two-hundred day moving average of $14.74. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $26.22. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of -5.48 and a beta of 1.30. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.14.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.05. As a group, research analysts expect that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Institutional Trading of Dyne Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Darwin Wealth Management LLC grew its holdings in Dyne Therapeutics by 0.5% in the third quarter. Darwin Wealth Management LLC now owns 173,517 shares of the company’s stock valued at $2,195,000 after purchasing an additional 861 shares during the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Dyne Therapeutics by 11.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock worth $91,000 after buying an additional 955 shares in the last quarter. Creative Planning boosted its position in shares of Dyne Therapeutics by 6.8% in the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock worth $196,000 after buying an additional 986 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Dyne Therapeutics by 25.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after buying an additional 1,109 shares in the last quarter. Finally, Caxton Associates LLP grew its holdings in shares of Dyne Therapeutics by 10.9% during the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after buying an additional 1,627 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.